CymitQuimica logo

CAS 1903768-17-1

:

danicopan

Description:
Danicopan, identified by its CAS number 1903768-17-1, is a small molecule drug that functions primarily as a complement inhibitor. It is designed to target and inhibit the complement component C3, which plays a crucial role in the immune response and inflammation. By modulating the complement system, danicopan aims to reduce tissue damage and inflammation associated with various diseases, particularly those involving excessive complement activation. The substance is being investigated for its therapeutic potential in conditions such as paroxysmal nocturnal hemoglobinuria (PNH) and other complement-mediated disorders. Danicopan is characterized by its specific binding affinity to C3, which helps in preventing the downstream effects of complement activation. Its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion, are essential for determining its efficacy and safety profile in clinical settings. As research continues, danicopan's role in managing complement-related diseases may provide new avenues for treatment and improve patient outcomes.
Synonyms:
  • ACH-0144471
  • DANICOPAN
  • 2-Pyrrolidinecarboxamide, 1-[2-[3-acetyl-5-(2-methyl-5-pyrimidinyl)-1H-indazol-1-yl]acetyl]-N-(6-bromo-2-pyridinyl)-4-fluoro-, (2S,4R)-
  • Danicopan
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 4 products.